Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents
出版年份 2011 全文链接
标题
Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents
作者
关键词
-
出版物
LEUKEMIA
Volume 26, Issue 1, Pages 73-85
出版商
Springer Nature
发表日期
2011-10-25
DOI
10.1038/leu.2011.310
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Toward deeper response in MM
- (2011) J. Blade et al. BLOOD
- Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
- (2011) J. Martinez-Lopez et al. BLOOD
- Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma
- (2011) S. Madan et al. BLOOD
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
- (2011) S. V. Rajkumar et al. BLOOD
- Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
- (2011) F. Gay et al. BLOOD
- Re-transplantation after bortezomib-based therapy
- (2011) Curly Morris et al. BRITISH JOURNAL OF HAEMATOLOGY
- Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression
- (2011) Jatin Shah et al. CANCER
- Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients
- (2011) T. Guglielmelli et al. EUROPEAN JOURNAL OF CANCER
- The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply)
- (2011) G. Visani et al. HAEMATOLOGICA
- Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma
- (2011) Bruno Paiva et al. JOURNAL OF CLINICAL ONCOLOGY
- Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
- (2011) Irene M Ghobrial et al. LANCET ONCOLOGY
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
- (2011) M A Dimopoulos et al. LEUKEMIA
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective
- (2011) H. Ludwig et al. ONCOLOGIST
- Ultra High-Risk Myeloma
- (2011) H. Avet-Loiseau Hematology-American Society of Hematology Education Program
- Relapsed Multiple Myeloma
- (2011) S. Lonial Hematology-American Society of Hematology Education Program
- Evidence-Based Mini-Review: Treatment Options for Patients with Relapsed/Refractory Myeloma Previously Treated with Novel Agents and High-Dose Chemotherapy and Autologous Stem-Cell Transplantation
- (2011) N. Shah et al. Hematology-American Society of Hematology Education Program
- Renal Insufficiency and Failure
- (2011) M. A. Dimopoulos et al. Hematology-American Society of Hematology Education Program
- Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment
- (2010) Ulrike Klein et al. ANNALS OF HEMATOLOGY
- Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
- (2010) A. Waage et al. BLOOD
- Balancing act for elderly myeloma
- (2010) A. Palumbo BLOOD
- Union of forces advances myeloma care
- (2010) A. K. Stewart BLOOD
- Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
- (2010) J.-L. Harousseau et al. BLOOD
- Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
- (2010) F. van Rhee et al. BLOOD
- Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial
- (2010) P. Moreau et al. BLOOD
- Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
- (2010) S. Bringhen et al. BLOOD
- Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy
- (2010) L Karlin et al. BONE MARROW TRANSPLANTATION
- The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study
- (2010) Stephen A. Schey et al. BRITISH JOURNAL OF HAEMATOLOGY
- The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
- (2010) Meletios Dimopoulos et al. CANCER
- Treatment of relapsed and refractory multiple myeloma in the era of novel agents
- (2010) Niels W.C.J. van de Donk et al. CANCER TREATMENT REVIEWS
- Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
- (2010) Jesús F. San-Miguel et al. Clinical Lymphoma Myeloma & Leukemia
- Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group
- (2010) Meral Beksac et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Emerging therapies for the treatment of relapsed or refractory multiple myeloma
- (2010) Meletios A. Dimopoulos et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Meeting the Unmet Needs in Anticoagulant Therapy
- (2010) EUROPEAN JOURNAL OF HAEMATOLOGY
- Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
- (2010) J.-L. Harousseau et al. HAEMATOLOGICA
- Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations
- (2010) B. Mohty et al. HAEMATOLOGICA
- Abnormal modulation of cell protective systems in response to ischemic/reperfusion injury is important in the development of mouse sickle cell hepatopathy
- (2010) A. Siciliano et al. HAEMATOLOGICA
- Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
- (2010) Pierre Wijermans et al. JOURNAL OF CLINICAL ONCOLOGY
- Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
- (2010) Asher A. Chanan-Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
- (2010) Maria-Victoria Mateos et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
- (2010) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma
- (2010) Henk Lokhorst et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
- (2010) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
- (2010) Marco Ladetto et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
- (2010) María-Victoria Mateos et al. LANCET ONCOLOGY
- Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
- (2010) Annemiek Broyl et al. LANCET ONCOLOGY
- Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
- (2010) A Palumbo et al. LEUKEMIA
- Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
- (2010) H Avet-Loiseau et al. LEUKEMIA
- Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
- (2010) M A Dimopoulos et al. LEUKEMIA
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- (2010) M Q Lacy et al. LEUKEMIA
- Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib
- (2009) Raman Sood et al. AMERICAN JOURNAL OF HEMATOLOGY
- The role of complete response in multiple myeloma
- (2009) J.-L. Harousseau et al. BLOOD
- Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
- (2009) S. Knop et al. BLOOD
- A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
- (2009) H. M. Lokhorst et al. BLOOD
- CR represents an early index of potential long survival in multiple myeloma
- (2009) M Wang et al. BONE MARROW TRANSPLANTATION
- Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
- (2009) Edward A. Stadtmauer et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis
- (2009) A. Kumar et al. HAEMATOLOGICA
- Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials
- (2009) Jean-Luc Harousseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Relapse/Refractory Myeloma Patient: Potential Treatment Guidelines
- (2009) Jesús F. San Miguel JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
- (2009) Cyrille Hulin et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
- (2009) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure
- (2009) Andrew Spencer et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- The use of novel agents in the treatment of relapsed and refractory multiple myeloma
- (2009) J P Laubach et al. LEUKEMIA
- Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
- (2009) E Kastritis et al. LEUKEMIA
- Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
- (2009) M A Dimopoulos et al. LEUKEMIA
- Treatment of Relapsed/Refractory Multiple Myeloma
- (2009) Efstathios Kastritis et al. SEMINARS IN HEMATOLOGY
- Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
- (2008) A. Palumbo et al. ANNALS OF ONCOLOGY
- Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
- (2008) M. Wang et al. BLOOD
- Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
- (2008) B. Barlogie et al. BLOOD
- Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
- (2008) A. Palumbo et al. BLOOD
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
- (2008) B. Paiva et al. BLOOD
- Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma
- (2008) R L Olin et al. BONE MARROW TRANSPLANTATION
- Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
- (2008) H de Lavallade et al. BONE MARROW TRANSPLANTATION
- Impact of early relapse after auto-SCT for multiple myeloma
- (2008) S Kumar et al. BONE MARROW TRANSPLANTATION
- The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma
- (2008) Ruben Niesvizky et al. BRITISH JOURNAL OF HAEMATOLOGY
- High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program
- (2008) Joseph R. Mikhael et al. BRITISH JOURNAL OF HAEMATOLOGY
- Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
- (2008) Juan José Lahuerta et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now